Table 2.

Statistical analysis for Felix-PDX and SH-SY5Y in vivo efficacy studies testing two doses of PF-06463922 (10 mg/kg/day and 3 mg/kg/day)

Tumor volumeEFS
Xenograft/PDXALK statusMYCN statusTreatmentP value vs. vehicle controlP value vs. crizotinibP value vs. PF-06463922 (3 mg/kg/day)P value vs. vehicle controlP value vs. crizotinibP value vs. PF-06463922 (3 mg/kg/day)
Felix-PDXMutated:NonamplifiedCrizotinib<0.00010.0008
F1245CPF-06463922 (3 mg/kg/day)<0.0001<0.0001<0.0001<0.0001
PF-06463922 (10 mg/kg/day)<0.0001<0.00010.3247<0.0001<0.00010.3428
SH-SY5YMutated:NonamplifiedCrizotinib0.00110.0502
F1174LPF-06463922 (3 mg/kg/day)<0.0001<0.0001<0.00010.0003
PF-06463922 (10 mg/kg/day)<0.0001<0.00010.6932<0.00010.0003NA